Ignite Creation Date:
2024-05-06 @ 5:59 PM
Last Modification Date:
2024-10-26 @ 2:39 PM
Study NCT ID:
NCT05501821
Status:
COMPLETED
Last Update Posted:
2023-11-03
First Post:
2022-08-04
Brief Title:
Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
Sponsor:
Kling Biotherapeutics BV
Organization:
Kling Biotherapeutics BV
Study Overview
Official Title:
A Phase I First-in-human Multicenter Open-label Dose Escalation Followed by an Expansion Phase Clinical Study of KBA1412 Given as Monotherapy or in Combination With Pembrolizumab in Adults With Advanced Solid Malignant Tumors
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to assess the safety and efficacy of KBA1412 a patient derived fully human monoclonal antibody targeting CD9 in patients with advanced solid malignant tumors
Detailed Description:
Patient interested in participation in a clinical study will be informed about the study and potential risks all patients giving written informed consent will undergo a 3-week screening period to determine their eligibility for entry in the study Patients will receive KBA1412 or KBA1412 in combination with pembrolizumab
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None